Investor Presentation First Nine Months of 2022
22
Investor presentation First nine months of 2022
Novo Nordisk has leading positions in diabetes, obesity and
haemophilia
Novo NordiskⓇ
Diabetes care
DKK
billion
1000
Obesity care
DKK
billion
#1
50%
24
Haemophilia
DKK
billion
#1
100%
100
#3
50%
20
800
40%
20
80%
80
40%
16
600
30%
60%
60
60
30%
12
400
20%
40%
40
40
20%
8
200
CAGR¹ value: 12.32%
10%
CAGR² value: 55.4%
20%
20
4
20
10%
CAGR³ value: 3.8%
0
0%
0
Aug
2017
Aug
2022
Aug
2020
Market value
Market value
NN value market share (RHS)
○ Global market position
NN value market share (RHS)
Global market position
1 CAGR for 5-year period; 2 CAGR for 2-year period; 3 CAGR for 3-year period; RHS: Right-hand side; Note: Annual sales figures for haemophilia A, B and bypassing agent segments, Recombinant and plasma derived products;
Source: Company reports for haemophilia market; IQVIA MAT, Aug 2022; Note: Diabetes and Obesity care market values are based on list prices in the US.
0%
0
Aug
2022
FY
2018
0%
FY
2021
Market value
NN value market share (RHS)
Global market position
NN: Novo Nordisk.View entire presentation